World journal of clinical oncology最新文献

{"title":"Health anxiety and work loss in patients diagnosed with serrated polyposis syndrome: A cross sectional study.","authors":"Angus Thompson, Natalie R Dierick, Louise Heiniger, Stuart N Kostalas","doi":"10.5306/wjco.v16.i2.97107","DOIUrl":"10.5306/wjco.v16.i2.97107","url":null,"abstract":"<p><strong>Background: </strong>Serrated polyposis syndrome (SPS) is a polyposis condition with neoplastic potential, but its psychological impact is not well understood.</p><p><strong>Aim: </strong>To assess health anxiety prevalence in a regional Australian cohort of SPS patients and explore factors influencing it, including workforce impacts of regular surveillance.</p><p><strong>Methods: </strong>This cross-sectional study screened patients aged 18-65 undergoing colonoscopy in a regional gastroenterology practice between January 2015 and June 2022. Eligible SPS patients were invited to participate. Data included the Short Health Anxiety Inventory, employment status, and previous demographic and medical findings.</p><p><strong>Results: </strong>Health anxiety was found in 21.57% of SPS patients, with anxious patients being significantly more concerned about surveillance (OR = 7.70). Patients lost an average of 11.04 work hours per colonoscopy.</p><p><strong>Conclusion: </strong>Health anxiety in SPS patients aligns with rates in other gastroenterology populations. Identifying it may improve management, though further research is needed to better understand prevalence and care improvements.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"97107"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686561/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493823","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pancreatic cancer: Future challenges and new perspectives for an early diagnosis.","authors":"Silvia Cocca, Giuseppina Pontillo, Marinella Lupo, Raffaele Lieto, Margherita Marocchi, Maria Marsico, Emanuela Dell'Aquila, Santi Mangiafico, Giuseppe Grande, Rita Conigliaro, Helga Bertani","doi":"10.5306/wjco.v16.i2.97248","DOIUrl":"10.5306/wjco.v16.i2.97248","url":null,"abstract":"<p><p>This editorial is a commentary on the case report by Furuya <i>et al</i> focusing on the challenging diagnosis of early pancreatic adenocarcinoma and new tools for an earlier diagnosis. Currently, pancreatic cancer still has a poor prognosis, mainly due to late diagnosis in an advanced stage. Two main precancerous routes have been identified as pathways to pancreatic adenocarcinoma: The first encompasses a large group of mucinous cystic lesions: intraductal papillary mucinous neoplasm and mucinous cystic neoplasm, and the second is pancreatic intraepithelial neoplasia. In the last decade the focus of research has been to identify high-risk patients, using advanced imaging techniques (magnetic resonance cholangiopancreatography or endoscopic ultrasonography) which could be helpful in finding \"indirect signs\" of early stage pancreatic lesions. Nevertheless, the survival rate still remains poor, and alternative screening methods are under investigation. Endoscopic retrograde cholangiopancreatography followed by serial pancreatic juice aspiration cytology could be a promising tool for identifying precursor lesions such as intraductal papillary mucinous neoplasm, but confirming data are still needed to validate its role. Probably a combination of cross-sectional imaging, endoscopic techniques (old and new ones) and genetic and biological biomarkers (also in pancreatic juice) could be the best solution to reach an early diagnosis. Biomarkers could help to predict and follow the progression of early pancreatic lesions. However, further studies are needed to validate their diagnostic reliability and to establish diagnostic algorithms to improve prognosis and survival in patients with pancreatic cancer.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"97248"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686566/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Programmed cell death 1 inhibitor sintilimab plus S-1 and gemcitabine for liver metastatic pancreatic ductal adenocarcinoma.","authors":"Shi-Qiong Zhou, Peng Wan, Seng Zhang, Yuan Ren, Hong-Tao Li, Qing-Hua Ke","doi":"10.5306/wjco.v16.i2.98079","DOIUrl":"10.5306/wjco.v16.i2.98079","url":null,"abstract":"<p><strong>Background: </strong>Pancreatic ductal adenocarcinoma (PDAC) is a highly aggressive cancer with poor prognosis. When it metastasizes to the liver, treatment options become particularly limited and challenging. Current treatment options for liver metastatic PDAC are limited, and chemotherapy alone often proves insufficient. Immunotherapy, particularly programmed cell death 1 (PD-1) inhibitors like sintilimab, shows potential efficacy for various cancers but has limited reports on PDAC. This study compares the efficacy and safety of sintilimab plus S-1 and gemcitabine <i>vs</i> S-1 and gemcitabine alone in liver metastatic PDAC.</p><p><strong>Aim: </strong>To explore the feasibility and effectiveness of combined PD-1 inhibitor sintilimab and S-1 and gemcitabine (combination group) <i>vs</i> S-1 and gemcitabine used alone (chemotherapy group) for treating liver metastatic pancreatic adenocarcinoma.</p><p><strong>Methods: </strong>Eligible patients were those with only liver metastatic PDAC, an Eastern Cooperative Oncology Group performance status of 0-1, adequate organ and marrow functions, and no prior anticancer therapy. Participants in the combination group received intravenous sintilimab 200 mg every 3 weeks, oral S-1 40 mg/m² twice daily on days 1-14 of a 21-day cycle, and intravenous gemcitabine 1000 mg/m² on days 1 and 8 of the same cycle for up to eight cycles or until disease progression, death, or unacceptable toxicity. Participants in the chemotherapy group received oral S-1 40 mg/m² twice daily on days 1-14 of a 21-day cycle and intravenous gemcitabine 1000 mg/m² on days 1 and 8 of the same cycle for up to eight cycles. Between June 2020 and December 2021, 66 participants were enrolled, with 32 receiving the combination treatment and 34 receiving chemotherapy alone.</p><p><strong>Results: </strong>The group receiving the combined therapy exhibited a markedly prolonged median overall survival (18.8 months compared to 10.3 months, <i>P</i> < 0.05) and progression-free survival (9.6 months <i>vs</i> 5.4 months, <i>P</i> < 0.05). compared to the chemotherapy group. The incidence of severe adverse events did not differ significantly between the two groups (<i>P</i> > 0.05).</p><p><strong>Conclusion: </strong>The combination of PD-1 inhibitor sintilimab with S-1 and gemcitabine demonstrated effectiveness and safety for treating liver metastatic PDAC, meriting further investigation.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"98079"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686555/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493875","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Targeting STAT3 with SH-4-54 suppresses stemness and chemoresistance in cancer stem-like cells derived from colorectal cancer.","authors":"Xu-Fan Zhang, Qian Chen, Qin Jiang, Qiong-Ying Hu","doi":"10.5306/wjco.v16.i2.97296","DOIUrl":"10.5306/wjco.v16.i2.97296","url":null,"abstract":"<p><strong>Background: </strong>Over the years, the numbers of treatment options for colorectal cancer (CRC) have increased, leading to notable improvements in the overall survival of CRC patients. Although therapy may initially yield positive results, the development of drug resistance can result in treatment failure and cancer recurrence. This resistance is often attributed to the presence of cancer stem cells (CSCs). These CSCs not only contribute to therapeutic resistance but also play crucial roles in the initiation and development of tumor metastasis.</p><p><strong>Aim: </strong>To investigate the antitumor effects of SH-4-54, which are mediated by targeting CSCs relative to treatment outcomes.</p><p><strong>Methods: </strong>CSCs were enriched by culturing CRC cells in serum-free medium. Hallmarks of stemness and IL-6/JAK2/STAT3 signaling were detected by Western blotting. Indicators of CSC malignancy, including proliferation, invasion, and tumor formation, were measured.</p><p><strong>Results: </strong>In this study, we employed SH-4-54, which exhibits anticancer activity in solid tumors through targeting the SH2 domain of both the signal transducer and activator of transcription (STAT)3 and the STAT5, and evaluated its effects on stemness and chemoresistance in colorectal CSCs. As expected, SH-4-54 treatment inhibited the phosphorylation of STAT3 (p-STAT3) and decreased the percentage of ALDH1A1-positive CRC cells. The addition of SH-4-54 dissociated colorectal spheroids and decreased the expression of stemness markers, including ALDH1A1, CD44 and Nanog. SH-4-54 treatment decreased IL-6/JAK2/STAT3 signaling by inhibiting p-STAT3 and thus inhibited spheroid formation by SW480 and LoVo cells. Moreover, SH-4-54 treatment inhibited indicators of malignancy, including cell proliferation, invasion, and tumor formation, in CSCs <i>in vitro</i> and <i>in vivo</i>. Notably, SH-4-54 treatment significantly increased chemosensitivity to oxaplatin.</p><p><strong>Conclusion: </strong>Taken together, these results indicate that SH-4-54 is a promising molecule that exerts antitumor effects on colorectal CSCs by inhibiting STAT3 signaling.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"97296"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686562/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mapping the landscape of gastric signet ring cell carcinoma: Overcoming hurdles and charting new paths for advancement.","authors":"Shu-Yuan Wang, Jing-Hang Wang, Run-Kai Chen, Zhen Yuan, Hao Cui, Bo Wei, Jian-Xin Cui","doi":"10.5306/wjco.v16.i2.98983","DOIUrl":"10.5306/wjco.v16.i2.98983","url":null,"abstract":"<p><strong>Background: </strong>In recent years, the global prevalence of gastric cancer (GC) has witnessed a progressive decrease, accompanied by a step-growth in the incidence of gastric signet ring cell carcinoma (GSRCC). As precision medicine concepts progress, GSRCC, a distinct sub-type of GC, has drawn considerable attention from researchers. However, there still persist some controversies regarding the associated research findings.</p><p><strong>Aim: </strong>To summarize the current obstacles and potential future directions for research on GSRCC.</p><p><strong>Methods: </strong>To begin with, all literature related to GSRCC published from January 1, 2004 to December 31, 2023 was subjected to bibliometric analysis in this article. Additionally, this paper analyzed the research data using CiteSpace, GraphPad Prism v8.0.2, and VOSviewer, which was obtained from the Web of Science Core Collection database. The analysis results were visually represented.</p><p><strong>Results: </strong>This study provided a comprehensive overview of the statistical characteristics of the 995 English articles related to GSRCC, including cited references, authors, journals, countries, institutions, and keywords. The popular keywords and clusters contain \"prognosis\", \"survival\", \"expression\", \"histology\", and \"chemotherapy\".</p><p><strong>Conclusion: </strong>The prognosis, precise definition and classification, as well as chemoresistance of GSRCC, continue to be crucial areas of ongoing research, whose directions are closely tied to advancements in molecular biology research on GSRCC.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"98983"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686557/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Overexpression pattern, function, and clinical value of proteasome 26S subunit non-ATPase 6 in hepatocellular carcinoma.","authors":"Sheng-Sheng Zhou, Yu-Ping Ye, Yi Chen, Da-Tong Zeng, Guang-Cai Zheng, Rong-Quan He, Bang-Teng Chi, Lei Wang, Qian Lin, Qin-Yan Su, Yi-Wu Dang, Gang Chen, Jia-Liang Wei","doi":"10.5306/wjco.v16.i2.99839","DOIUrl":"10.5306/wjco.v16.i2.99839","url":null,"abstract":"<p><strong>Background: </strong>In recent years, many studies have shown that proteasome 26S subunit non-ATPase 6 (PSMD6) plays an important role in the occurrence and development of malignant tumours. Unfortunately, there are no reports on the evaluation of the potential role of PSMD6 in hepatocellular carcinoma (HCC).</p><p><strong>Aim: </strong>To comprehensively evaluate the overexpression pattern and clinical significance of PSMD6 in HCC tissues.</p><p><strong>Methods: </strong>This study integrated PSMD6 mRNA expression profiles from 4672 HCC and 3667 non-HCC tissues, along with immunohistochemical scores from 383 HCC and adjacent tissues, to assess PSMD6 overexpression in HCC. Clustered regularly interspaced short palindromic repeats knockout technology evaluated PSMD6's essential role in HCC cell growth. Functional enrichment analysis explored the molecular mechanism of PSMD6 abnormalities in HCC. Drug sensitivity analysis and molecular docking analysed the effect of abnormal expression of PSMD6 on the drug sensitivity of HCC cells.</p><p><strong>Results: </strong>The results of 41 external and two internal datasets showed that PSMD6 mRNA (SMD = 0.26, 95%CI: 0.09-0.42, <i>P</i> < 0.05) and protein (SMD = 2.85, 95%CI: 1.19-4.50, <i>P</i> < 0.05) were significantly overexpressed in HCC tissues. The integrated analysis results showed that PSMD6 had a significant overexpression pattern in HCC tissues (SMD = 0.40, 95%CI: 0.15-0.66, <i>P</i> < 0.05). PSMD6 knockout inhibited HCC cell growth (chronos scores < -1). Functional enrichment implicated ribosome biogenesis and RNA splicing. Significant enrichment of signalling pathways such as RNA degradation, ribosomes, and chemical carcinogenesis-reactive oxygen species. Drug sensitivity analysis and a molecular docking model showed that high expression of PSMD6 was associated with the tolerance of HCC cells to drugs such as ML323, sepantronium bromide, and GDC0810. Overexpressed PSMD6 effectively distinguished HCC tissues (AUC = 0.75, 95%CI: 0.71-0.79).</p><p><strong>Conclusion: </strong>This study was the first to discover that PSMD6 was overexpressed in HCC tissues. PSMD6 is essential for the growth of HCC cells and may be involved in ribosome biogenesis and RNA splicing.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"99839"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686554/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493918","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pembrolizumab-induced Guillain-Barré syndrome in triple-negative breast cancer: A case report.","authors":"Phani Bhavana Cherukuri, Muhammad Tayyeb, Sai Rakshith Gaddameedi, Doantrang Du, Trishala Meghal","doi":"10.5306/wjco.v16.i2.97823","DOIUrl":"10.5306/wjco.v16.i2.97823","url":null,"abstract":"<p><strong>Background: </strong>The programmed cell death protein 1 inhibitor pembrolizumab has become a key treatment for various cancers, including triple-negative breast cancer. However, it is associated with immune-related adverse events, including rare but serious neurological complications such as Guillain-Barré syndrome (GBS). GBS is a potentially life-threatening autoimmune disorder characterized by muscle weakness and paralysis. We present a unique case of pembrolizumab-induced GBS to highlight the importance of recognizing this complication and managing it promptly in patients receiving immune checkpoint inhibitors.</p><p><strong>Case summary: </strong>A 69-year-old woman with a medical history of hypertension, anxiety, depression, and stage IIIB triple-negative breast cancer treated with pembrolizumab, carboplatin, and paclitaxel, presented to the emergency department with a 1-month history of tingling, lower extremity weakness, and shooting pain. Symptoms progressed to global weakness, ascending paralysis, and double vision. Neurological examination revealed significant lower extremity weakness and sensory deficits. Magnetic resonance imaging of the lumbar spine and cerebrospinal fluid analysis confirmed GBS. Initial treatment with intravenous immunoglobulin led to relapse, requiring additional intravenous immunoglobulin and high-dose glucocorticoids. The patient's condition improved, pembrolizumab therapy was permanently discontinued, and she was discharged to a rehabilitation facility.</p><p><strong>Conclusion: </strong>Pembrolizumab can induce GBS, necessitating early recognition, prompt diagnosis, and multidisciplinary management to prevent serious complications.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"97823"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686565/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Correlation between gut microbiota and tumor immune microenvironment: A bibliometric and visualized study.","authors":"Zheng-Jun Hu, Hui-Rong Zhu, Yong-Jie Jin, Pan Liu, Xiao-Wei Yu, Yu-Ren Zhang","doi":"10.5306/wjco.v16.i2.101611","DOIUrl":"10.5306/wjco.v16.i2.101611","url":null,"abstract":"<p><strong>Background: </strong>In recent years, numerous reports have been published regarding the relationship between the gut microbiota and the tumor immune microenvironment (TIME). However, to date, no systematic study has been conducted on the relationship between gut microbiota and the TIME using bibliometric methods.</p><p><strong>Aim: </strong>To describe the current global research status on the correlation between gut microbiota and the TIME, and to identify the most influential countries, research institutions, researchers, and research hotspots related to this topic.</p><p><strong>Methods: </strong>We searched for all literature related to gut microbiota and TIME published from January 1, 2014, to May 28, 2024, in the Web of Science Core Collection database. We then conducted a bibliometric analysis and created visual maps of the published literature on countries, institutions, authors, keywords, references, <i>etc.,</i> using CiteSpace (6.2R6), VOSviewer (1.6.20), and bibliometrics (based on R 4.3.2).</p><p><strong>Results: </strong>In total, 491 documents were included, with a rapid increase in the number of publications starting in 2019. The country with the highest number of publications was China, followed by the United States. Germany has the highest number of citations in literature. From a centrality perspective, the United States has the highest influence in this field. The institutions with the highest number of publications were Shanghai Jiao Tong University and Zhejiang University. However, the institution with the most citations was the United States National Cancer Institute. Among authors, Professor Giorgio Trinchieri from the National Institutes of Health has the most local impact in this field. The most cited author was Fan XZ. The results of journal publications showed that the top three journals with the highest number of published papers were <i>Frontiers in Immunology, Cancers,</i> and <i>Frontiers in Oncology.</i> The three most frequently used keywords were gut microbiota, tumor microenvironment, and immunotherapy.</p><p><strong>Conclusion: </strong>This study systematically elaborates on the research progress related to gut microbiota and TIME over the past decade. Research results indicate that the number of publications has rapidly increased since 2019, with research hotspots including \"gut microbiota\", \"tumor microenvironment\" and \"immunotherapy\". Exploring the effects of specific gut microbiota or derived metabolites on the behavior of immune cells in the TIME, regulating the secretion of immune molecules, and influencing immunotherapy are research hotspots and future research directions.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"101611"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686564/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular mechanism of pancreatic ductal adenocarcinoma: The heterogeneity of cancer-associated fibroblasts and key signaling pathways.","authors":"Zhong-Yuan Hu, Ding Ding, Yu Song, Ya-Feng Deng, Cheng-Ming Zhang, Tao Yu","doi":"10.5306/wjco.v16.i2.97007","DOIUrl":"10.5306/wjco.v16.i2.97007","url":null,"abstract":"<p><p>Pancreatic ductal adenocarcinoma stands out as an exceptionally fatal cancer owing to the complexities associated with its treatment and diagnosis, leading to a notably low five-year survival rate. This study offers a detailed exploration of epidemiological trends in pancreatic cancer and key molecular drivers, such as mutations in <i>CDKN2A</i>, <i>KRAS</i>, <i>SMAD4</i>, and <i>TP53</i>, along with the influence of cancer-associated fibroblasts (CAFs) on disease progression. In particular, we focused on the pivotal roles of signaling pathways such as the transforming growth factor-β and Wnt/β-catenin pathways in the development of pancreatic cancer and investigated their application in emerging therapeutic strategies. This study provides new scientific perspectives on pancreatic cancer treatment, especially in the development of precision medicine and targeted therapeutic strategies, and demonstrates the importance of signaling pathway research in the development of effective therapeutic regimens. Future studies should explore the subtypes of CAFs and their specific roles in the tumor microenvironment to devise more effective therapeutic methods.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"97007"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686552/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Turning the tide: From cervical cancer's grip to complete response: A case report.","authors":"Shatha Abutaha, Abdulla Alzibdeh, Issa Mohamad, Lina Wahbeh, Samer Salah, Ramiz Abuhijlih, Fawzi Abuhijla","doi":"10.5306/wjco.v16.i2.98219","DOIUrl":"10.5306/wjco.v16.i2.98219","url":null,"abstract":"<p><strong>Background: </strong>Cervical cancer is a formidable global health issue, particularly affecting women in lower-middle-income countries with little or no access to preventative vaccines, screening programs, and treatment modalities. The case report presents a unique case of a large cervical cancer achieving complete response (CR) with concurrent chemoradiotherapy (CCRT), highlighting the effectiveness of this treatment approach even in advanced stages and underscoring the importance of adaptive radiotherapy (RT) in optimizing patient outcomes.</p><p><strong>Case summary: </strong>We present the case of a 53-year-old woman who presented with four years of abnormal vaginal bleeding and was found to have p16-positive, moderately differentiated cervical squamous cell carcinoma. The tumor measured 14 cm × 12 cm × 8 cm, the largest size reported in the literature to achieve CR with CCRT. Despite this monumental feat, the patient remained disease-free and is currently on follow-up for 2 years; however, she continued to suffer from substantial morbidity caused by a vesicovaginal fistula and hydronephrosis, underscoring the continuing impact of cervical cancer on quality of life.</p><p><strong>Conclusion: </strong>In this case report, we highlight the effectiveness of CCRT in achieving CR, even in cases of bulky cervical cancer, with adaptive RT offering a customized strategy to improve patient outcomes. We also emphasize the necessity for multidisciplinary team discussions and highlight the need for strategies to mitigate treatment-related toxicities and long-term complications.</p>","PeriodicalId":23802,"journal":{"name":"World journal of clinical oncology","volume":"16 2","pages":"98219"},"PeriodicalIF":2.6,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11686556/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143493924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}